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Aims: The management of asymptomatic severe mitral regurgitation remains controversial. The aim of the study was
to assess the long-term survival, incidence of cardiac complications, factors that predict outcome, and effect of mitral
surgery on the long-term prognosis of patients with asymptomatic severe mitral regurgitation amenable to valve repair.
Methods: One hundred ninety-two asymptomatic patients (mean age, 63  13 years) with severe degenerative
mitral regurgitation diagnosed by 2-dimensional echocardiography between 1990 and 2001 were prospectively
followed for a median of 8.5 years.
Results: Overall, cardiovascular, and event-free survival was evaluated in 2 groups of patients: a ‘‘conservative
approach’’ group (n¼ 67) and an ‘‘early surgery’’ group (n¼ 125). Outcomes were also analyzed among patients
with atrial fibrillation, pulmonary hypertension, or both, as well as in patients free of any mitral regurgitation com-
plications. In the whole population, 10-year overall survival was significantly lower with the conservative ap-
proach than early surgery (50%  7% vs 86%  4%, log-rank< 0.0001). Similar results were obtained in
the subgroups with atrial fibrillation and/or pulmonary hypertension. The 10-year propensity-matched score-ad-
justed hazards ratio for overall mortality, cardiac mortality, and cardiovascular events for the conservative treat-
ment were 5.21, 4.83, and 4.40, respectively.
Conclusion: Our results show that the outcome of asymptomatic patients with severe degenerative mitral regur-
gitation is better with an early surgical approach rather than a more conservative treatment strategy. (J Thorac
Cardiovasc Surg 2009;138:1339-48)
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Degenerative mitral regurgitation (MR) is the second most
frequently encountered valvular disease in Western coun-
tries and is often discovered fortuitously in still asymptom-
atic patients.1,2 Although surgery is the only proven
efficient therapeutic option for patients with severe MR, its
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cording to current American Heart Association/American
College of Cardiology and European Society of Cardiology
guidelines,3,4 surgery is usually not recommended in asymp-
tomatic patients with preserved left ventricular (LV) func-
tion. Both sets of guidelines nonetheless indicate that
surgery may be considered, but is not compulsory, when
atrial fibrillation (AF) ensues or in the presence of pulmo-
nary hypertension.
Despite these recommendations, a number of authors
have called for a different standard of referring patients
with chronic MR to surgery.5 They suggest that if the mitral
valve is both severely regurgitant and repairable, postponing
surgery exposes the patient to unnecessary risk in an era in
which mitral valve repair in high-volume specialized centers
has a very low morbidity and mortality.6 Thus, they recom-
mend elective surgery early rather than late in such patients.
On the other hand, other authors have advocated to postpone
surgery until the end points in the guidelines are met.7 They
argue that, according to most database reports, operative
mortality remains relatively high and the majority of patients
who have mitral valve surgery ultimately receive a mitral
prosthesis,1,8,9 which is associated with markedly higherardiovascular Surgery c Volume 138, Number 6 1339
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DAbbreviations and Acronyms
AF ¼ atrial fibrillation
CABG ¼ coronary artery bypass graft surgery
LV ¼ left ventricular
MR ¼ mitral regurgitation
operative mortality and prosthetic valve-related long-term
mortality and morbidity.10,11 Recent data suggest that such
a conservative approach is safe, particularly when patients
can be followed closely and diligently in a structured envi-
ronment by an interested expert.7
In view of this controversy, the present study assessed
long-term survival, incidence of cardiac complications, fac-
tors that predict outcome, and effect of mitral surgery on
the long-term prognosis of patients with asymptomatic severe
MR amenable to valve repair. In particular, we sought to de-
termine whether an early surgical approach would benefit
asymptomatic patients who do not meet any guidelines
criteria (ie, patients without LV dilatation or dysfunction,
AF, or pulmonary hypertension). In patients initially treated
conservatively, we also investigated whether more regular
follow-up and stricter application of the guidelines are associ-
ated with a better outcome. To test these hypotheses, we con-
ducted a follow-up study of patients with severe MR due to
mitral valve prolapse, as delineated by echocardiography.
METHODS
Study Population
The study population consisted of every patient in whom severe ( grade 3)
MR was diagnosed with the use of Doppler echocardiography between Janu-
ary 1, 1990, and December 31, 2001, at the Cliniques Universitaires St-Luc in
Brussels. Exclusion criteria were age>85 years, associated mitral valve steno-
sis, previous valve surgery, associated congenital heart disease, and significant
aortic valve disease. Patients with class I indication for surgery (ie, New York
Heart Association class III or IV, LV ejection fraction<60%, or LV end-sys-
tolic internal diameter>45 mm) were also excluded.3,4 Patients with coronary
artery disease and those who had bypass grafting were not excluded.
Information on postdiagnosis events was obtained for all patients be-
tween December 2006 and April 2007. Cardiac events and causes of death
were ascertained by contacting the patient’s physicians and reviewing death
certificates, coroner’s reports, or autopsy records.
Echocardiography
Echocardiographic data were obtained with commercially available ul-
trasound systems. All patients had a comprehensive examination, including
M-mode and 2-dimensional echocardiography, as well as conventional and
color Doppler examinations. All tests were conducted by experienced echo-
cardiographers. Mitral valve prolapse was considered in the presence of
a Carpentier type II mitral valve dysfunction12 (ie, in the presence of excess
leaflet motion with part of the leaflet tips overriding the plane of the mitral
annulus causing failure of leaflet coaptation). Flail leaflet was diagnosed
when the leaflet tip turned outward, becoming concave toward the left
atrium, and was considered a definite sign of severe MR.
The severity of MR was assessed semiquantitatively on a scale of 1þ to
4þby an integrated approach that included valve morphology, the size of the
regurgitant jet in the left atrium, the proximal regurgitant jet width, and pul-1340 The Journal of Thoracic and Cardiovascular Sumonary venous flow pattern. Severe MR was defined as a holosystolic,
grade  3þMR. The approach to semiquantification used in the present
study was in agreement with prevailing guidelines at the time of patient’s
recruitment.13
LV diameters, fractional shortening, and ejection fraction, as well as left
atrial size and systolic pulmonary artery pressure (using tricuspid regurgi-
tant velocity), were measured as recommended.14
Statistical Analysis
All analyses were conducted using the SPSS software (version 12.0,
SPSS Corp, Chicago, Ill). Continuous variables were expressed as mean
 standard deviation, categorical variables as counts and percentages,
and follow-up times as median and range. Differences between groups
were analyzed with a one-way analysis of variance. Overall, cardiovascular,
and event-free survival functions were computed with the Kaplan-Meier
method and compared using the log-rank chi-square test. Cardiac events
were defined as cardiac deaths, need for mitral surgery (including reopera-
tions), mitral endocarditis, complete atrioventricular block, nonfatal stroke,
and acute coronary syndromes. For each patient included in the study, the
corresponding average age- and gender-specific annual mortality of the
Belgian general population was obtained.15 On the basis of these mortality
data, the probability of cumulative expected survival was determined and
an expected survival curve was constructed. Several separate subgroup
analyses were performed. The first subgroup analysis investigated the effect
of frequency of follow-up visits on outcome and appropriateness of opera-
tive criteria with prevailing guidelines. A second subgroup analysis aimed
at evaluating the prognostic impact of AF, pulmonary hypertension, or both
was performed in patients who presented with one or both of these features
at the entrance into the study. Finally, a last subgroup analysis was con-
ducted in patients who did not meet any class I or IIa guidelines criteria
(ie, patients without LV dilatation or dysfunction, AF, or pulmonary hyper-
tension).3,4
All clinical, angiographic, and echocardiographic variables were also
proposed for inclusion into a Cox proportional hazards survival model for
determination of the factors independently associated with outcome. For
this purpose, an interactive stepwise selection procedure using the maxi-
mum partial likelihood ratio chi-square statistic (c2 test) to enter (<.05 level)
or to remove (>.05 level) a covariate into the model was used. Variables
were entered until no F-to-enter statistics were significant at the 5% level
and until the mean squared error reached a minimum. Differences between
groups were analyzed with a one-way analysis of variance.
To overcome the absence of randomization, we performed a propensity
analysis. The theoretical basis of propensity score analysis has been pub-
lished elsewhere.16 Briefly, propensity scores are used to create matched
pairs or matched sets that are balanced with respect to many observed cova-
riates. The resulting matched sets are heterogeneous within the covariates,
but the covariates aim to have uniform distributions in treated and control
groups, which makes the groups as a whole comparable.17 Propensity score
analysis was carried out in our study to estimate the probability that a patient
might have early surgery versus conservative treatment and to eliminate the
effect of nonrandomization and selection bias. First, logistic regression anal-
ysis of several baseline variables was performed to generate a single propen-
sity score for each patient. Practically, we included all possible covariates
that we were able to trace and that were expected to be a potential contrib-
uting factor for determining whether or not a patient would receive an early
surgery strategy or a conservative treatment strategy (Table 1). The model
had an area under the receiver operating characteristic curve of 0.79. Sec-
ond, we used a subset analysis, in which patients were grouped according
to the magnitude of their propensity score into 5 quintiles, after which their
characteristics and outcomes were compared within these quintiles (Table
1). Groups with similar propensity scores appeared to be reasonably well
matched with respect to all characteristics. We then calculated the 10-year
propensity-matched score-adjusted hazards ratio for each end point using
a Cox regression model.rgery c December 2009
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DRESULTS
Baseline Characteristics
The clinical characteristics of the 192 patients who met
the inclusion criteria are shown in Table 2. Patients were
separated into 2 groups according to the initial treatment
option. Sixty-seven patients initially treated conservatively
were included in the conservative approach group, whereas
the remaining 125 patients, who were operated on within the
first 3 months after diagnosis, were included in the early sur-
gery group.
In the early surgery group, surgery always consisted of
mitral valve repair. Twenty-seven patients also had coronary
artery bypass graft surgery (CABG).
Overall and Cardiovascular Survival
During a median follow-up of 8.5 years, 45 patients died,
31 (46%) in the conservative approach group and 14 (11%)
in the early surgery group. Among the 45 patients who died
during follow-up, the cause of death was cardiac in 24 pa-
tients (postoperative death in 2, intractable heart failure in
9, sudden cardiac death in 7, thromboembolic or hemor-
rhagic stroke in 3, and miscellaneous factors in 3) and non-
cardiac in 21 patients. Figure 1 shows the Kaplan-Meier
curves for overall survival in the 2 groups of patients, to-
gether with that expected in the age- and gender-adjusted
Belgian population. Ten-year overall and cardiovascular
survival was significantly lower in the conservative ap-
proach than in the early surgery group.
Because 27 patients from the early surgery group had
combined CABG and mitral valve repair, we evaluated
whether CABG contributed to their better survival. After
10 years of follow-up, patients having combined mitral
valve repair and CABG had a poorer overall and cardiovas-
cular survival (58% 12% and 77% 10%, respectively)
than patients having mitral valve repair alone (94%  3%
and 97%  2%, respectively, both log rank< .01).
Need for Surgery and Nonfatal Events
During follow-up, 23 patients in the conservative ap-
proach group had mitral surgery. Mitral surgery was indi-
TABLE 1. Number of patients who were matched in each quintile
after propensity scoring*
Quintile
Early surgery
(n ¼ 125)
Conservative treatment
(n ¼ 67) P value
1st quintile (n,%) 33 (27%) 3 (4%) .11
2nd quintile (n,%) 33 (26%) 6 (9%) .66
3rd quintile (n,%) 25 (20%) 14 (21%) .10
4th quintile (n,%) 23 (18%) 15 (22%) .37
5th quintile (n,%) 11 (8%) 29 (43%) .11
*Covariates used for individual propensity scores: age, sex, height, weight, smoking,
cholesterol value, hypertension, diabetes mellitus, family history of coronary artery
disease, creatinine value, atrial fibrillation, left ventricular ejection fraction, heart
rate, left atrial size, left ventricular end-diastolic and end-systolic diameters, systolic
tricuspid gradient, prolapse type. A P value indicates the statistical difference between
the propensity score within each quintile.The Journal of Thoracic and Ccated on the basis of class I guidelines criteria in 17,
class IIa guidelines criteria in 2, infective endocarditis in
3, and need for CABG in 1. Median delay between the de-
velopment of guidelines criteria and surgery was 49 days
(range 28–139 days). Seven patients in the early surgery
group also needed a reoperation, 5 because of recurrent se-
vere MR, 1 because of mitral stenosis, and 1 because of
a voluminous atrial thrombus. Eleven additional nonfatal
cardiac events (4 strokes, 3 complete atrioventricular
blocks, 3 acute myocardial infarctions, and 1 infective en-
docarditis) also occurred during follow-up. As shown in
Figure 1, 10-year cardiac event–free survival was signifi-
cantly lower in the conservative approach than in the early
surgery group.
Impact of AF, Pulmonary Hypertension, or Both on
Long-Term Outcome
A total of 60 patients (16 in the conservative approach
group and 44 in the early surgery group) presented with
AF, pulmonary hypertension, or both at the time of diagno-
sis. Their baseline characteristics are shown in Table 3. Dur-
ing follow-up, 20 of these patients died, 13 (81%) in the
conservative approach group and 7 (16%) in the early sur-
gery group. The cause of death was cardiac in 13 patients
(postoperative death in 2, intractable heart failure in 4, sud-
den cardiac death in 3, thromboembolic or hemorrhagic
stroke in 1, and miscellaneous factors in 3) and noncardiac
in 7 patients. As shown in Figure 2, 10-year overall, cardio-
vascular, and cardiac event–free survivals were significantly
lower in the conservative approach than in the early surgery
group.
TABLE 2. Baseline characteristics of the overall population
Early surgery
(n ¼ 125)
Conservative
approach
(n ¼ 67) P value
Age (y) 62  12 64  15 .54
Male gender (%) 71 69 .74
Height (m) 1.72  0.08 1.70  0.09 .23
Weight (kg) 72  12 70  13 .20
Diabetes mellitus (%) 7 8 .8
Hypertension (%) 33 46 .06
Smoking (%) 18 27 .13
Total cholesterol (mg/dL) 217 36 213  43 .60
Serum creatinine (mg/dL) 0.99  0.25 0.98  0.35 .71
Prolapse type (%) 67/12/21 70/12/18 .9
LVEDD (mm) 59  7 55  7 <.0001
LVESD (mm) 36  5 33  5 <.0001
LVEF (%) 70  6 71  7 .21
LA size (mm) 49  9 47  8 .06
AF 24% 18% .36
Systolic tricuspid gradient
(mm Hg)
33  13 29  11 .08
AF, Atrial fibrillation; LA size, left atrial size; LVEDD, left ventricular end-diastolic
diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic
diameter; prolapse type, posterior/anterior/bileaflet.ardiovascular Surgery c Volume 138, Number 6 1341
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DFIGURE 1. Kaplan-Meier curves for overall (A), cardiovascular (B), and cardiovascular (CV) event-free (C) survival compared with patients having early
surgery (solid line), those treated conservatively (dashed line), and the age- and gender-matched Belgian population (dashed dotted line). Numbers at bottom
indicate patients at risk.Survival in Patients Free From Any MR
Complications
A total of 132 patients (51 in the conservative approach
group and 81 in the early surgery group) were free of any
MR complications at the time of diagnosis. Their baseline
characteristics are shown in Table 4. During the 10-year fol-
low-up period, 25 of these patients died, 18 (35%) in the
conservative approach group and 7 (9%) in the early surgery
TABLE 3. Baseline characteristics of asymptomatic patients with AF,
pulmonary hypertension, or both
Early surgery
(n ¼ 44)
Conservative
approach
(n ¼ 16) P value
Age (y) 67  11 71  10 .18
Male gender (%) 68 63 .76
Height (m) 1.71  0.07 1.69  0.11 .38
Weight (kg) 72  14 71  14 .87
Diabetes mellitus (%) 5 6 .99
Hypertension (%) 39 19 .22
Smoking (%) 18 25 .72
Total cholesterol (mg/dL) 214  40 195  46 .17
Serum creatinine (mg/dL) 1.10  0.26 1.10  0.44 .72
Prolapse type (%) 73/13/14 87/13/0 .30
LVEDD (mm) 58  7 52  5 .02
LVESD (mm) 36  5 31  5 <.0001
LVEF (%) 68  7 71  8 .20
LA size (mm) 50  9 52  10 .59
AF (%) 68 75 .99
Systolic tricuspid
gradient (mm Hg)
42  14 37  13 .25
Pulmonary hypertension (%) 38 38 .99
AF, Atrial fibrillation; LA size, left atrial size; LVEDD, left ventricular end-diastolic
diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic
diameter; prolapse type, posterior/anterior/bileaflet.1342 The Journal of Thoracic and Cardiovascular Sgroup. The cause of death was cardiac in 11 patients (intrac-
table heart failure in 5, sudden cardiac death in 4, and throm-
boembolic or hemorrhagic stroke in 2) and noncardiac in 14
patients. During follow-up, 20 patients in the conservative
approach group had mitral surgery, whereas 6 patients in
the early surgery group needed a reoperation. Eight addi-
tional nonfatal cardiac events (2 strokes, 3 complete atrio-
ventricular blocks, 2 acute myocardial infarctions, and 1
infective endocarditis) also occurred. As shown in Figure 3,
10-year overall, cardiovascular, and cardiac event–free sur-
vival was significantly lower in the conservative approach
than in the early surgery group.
Effects of Follow-up Regularity and Quality on
Outcome in the Conservative Approach Group
To evaluate the potential influence of the regularity and
quality of follow-up visits on outcome, patients from the
conservative approach group were further subdivided into
2 subgroups according to whether they were seen by a regis-
tered cardiologist at least once a year (n ¼ 43) or not (n ¼
24). Among the 43 patients who were regularly followed,
23 had mitral surgery during follow-up. Indications for sur-
gery were reported above. Among the 20 patients who were
regularly followed but were not operated on, 4 also devel-
oped class I or IIa indications for surgery but were denied
surgery on the basis of age-related comorbidities. Interest-
ingly, none of the patients with irregular follow-up had mi-
tral surgery during follow-up. As shown in Figure 4, patients
having a regular follow-up had a significantly better 10-year
overall survival than patients having no follow-up or having
irregular follow-up. Despite this, overall 10-year survival
was less in regularly followed patients from the conservative
approach group than in patients having early surgery.urgery c December 2009
Montant et al Acquired Cardiovascular DiseaseFIGURE 2. Kaplan-Meier curves for overall (A), cardiovascular (B), and cardiovascular (CV) event-free (C) survival compared with patients with atrial
fibrillation, pulmonary hypertension, or both who had early surgery (solid line) or were treated conservatively (dashed line). Numbers at bottom indicate pa-
tients at risk. The dashed dotted line represents the age- and gender-matched Belgian population.A
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DCox Proportional-Hazards Survival Analysis
To assess the factors potentially associated with 10-year
overall and cardiovascular survival, 2 different Cox survival
models were built to which all the clinical and echocardio-
graphic parameters available were proposed for inclusion.
Among these variables, only the initial treatment strategy
and age were independently associated with the time to death
(Table 5). Similar results were obtained after removal of the pa-
tients who had concomitant CABG (n ¼ 32) from both the
early surgery and conservative approach groups (hazards ratio
treatment strategy, 9.25 [3.53–24.21]; hazards ratio age, 1.08
[1.04–1.11]). Figure 5 shows the age-adjusted Kaplan-Meier
curves for overall survival in the 2 groups of patients, together
with that expected in the age- and gender-adjusted Belgian
TABLE 4. Baseline characteristics of asymptomatic patients without
LV dysfunction, LV dilatation, AF, or pulmonary hypertension
Early surgery
(n ¼ 81)
Conservative
approach
(n ¼ 51) P value
Age (y) 60  13 61  16 .57
Male gender (%) 73 71 .84
Height (m) 1.72  0.09 1.70  0.09 .33
Weight (kg) 73  11 70  12 .13
Diabetes mellitus (%) 9 8 .99
Hypertension (%) 30 55 .003
Smoking (%) 19 28 .28
Total cholesterol (mg/dL) 218  34 218  41 .95
Serum creatinine (mg/dL) 0.96  0.24 0.94  0.31 .74
Prolapse type (%) 64/11/25 65/12/23 .99
LVEDD (mm) 60  8 56  7 .002
LVESD (mm) 36  5 34  5 .004
LVEF (%) 70  6 71  7 .55
LA size (mm) 49  8 45  7 .012
Systolic tricuspid gradient
(mm Hg)
28  8 25  7 .12
AF, Atrial fibrillation; LA size, left atrial size; LVEDD, left ventricular end-diastolic
diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic
diameter; prolapse type, posterior/anterior/bileaflet.The Journal of Thoracic and Cpopulation. Even after adjustment for age, the 10-year overall
and cardiovascular survivals remained significantly lower in
the conservative approach than in the early surgery group.
Propensity Analysis
The 10-year propensity-matched score adjusted hazards
ratio was calculated for each end point using a Cox regres-
sion model. The results are shown in Table 6.
DISCUSSION
The management of asymptomatic patients with severe
MR is an area of intense controversy because there are no
randomized trials to support any particular course of action.
On the one hand, the good results of valve repair and the
potential risk of postoperative LV dysfunction are incentives
for early surgery.5,18,19 On the other hand, even in low-risk
cases, there is a small but definite risk of surgical mortality.8-10
To provide new insights into this controversy, we performed
a follow-up study of asymptomatic patients with severe de-
generative MR amenable to valve repair who were diagnosed
at our institution between 1990 and 2001. Our results can be
summarized as follows:
1. On average, asymptomatic patients who had early surgi-
cal correction of severe degenerative MR incurred lower
mortality and morbidity than patients who were followed
more conservatively. They also tended to have better
overall survival than that expected in the age- and gen-
der-matched Belgian population.
2. Among asymptomatic patients with severe degenerative
MR who were not operated on early, those who were reg-
ularly followed by a registered cardiologist had a higher
likelihood of being referred in a timely manner to surgery
and hence had better long-term outcome than those who
were not.
3. Asymptomatic patients presenting with AF, pulmonary
hypertension, or both had an extremely poor prognosis
when treated conservatively.ardiovascular Surgery c Volume 138, Number 6 1343
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DFIGURE 3. Kaplan-Meier curves for overall (A), cardiovascular (B), and cardiovascular (CV) event-free (C) survival compared with patients without left
ventricular dysfunction, left ventricular dilatation, atrial fibrillation, or pulmonary hypertension who had early surgery (solid line) and or were treated con-
servatively (dashed line). Numbers at bottom indicate patients at risk. The dashed dotted line represents the age- and gender-matched Belgian population.4. In asymptomatic patients with uncomplicated MR (ie,
without LV dilatation or dysfunction, AF, or pulmonary
hypertension), early surgery was associated with better
overall, cardiovascular, and event-free survival.
Rationale for Early Intervention in Severe
Degenerative MR
To consider surgical intervention early in a disease pro-
cess, it must be demonstrated that the surgical procedure im-
proves the overall survival and quality of life in comparison1344 The Journal of Thoracic and Cardiovascular Suto the disease process natural course. Degenerative MR is
a progressive disorder20 that increases the LV filling pres-
sures, causes enlargement of the left atrium and ventricle,
and eventually leads to LV dysfunction and congestive heart
failure.19 Previous studies have demonstrated that the pres-
ence of LV dysfunction or heart failure in a preoperative
patient negatively affects the postoperative outcome,21,22
suggesting that surgical correction should be performed be-
fore the development of the functional impairment.
For such a strategy to be applicable, the immediate and
long-term benefits of mitral valve surgery should largelyFIGURE 4. Kaplan-Meier curves for overall (A), cardiovascular (B), and cardiovascular (CV) event-free (C) survival compared with patients having early
surgery (solid line), those treated conservatively and followed regularly (dashed line), or those treated conservatively and with irregular follow-up (dashed
dotted line). Numbers at bottom indicate patients at risk.rgery c December 2009
Montant et al Acquired Cardiovascular DiseaseTABLE 5. Cox proportional hazards analysis
Univariate Analysis Multivariate Analysis
HR (95% CI) P value HR (95% CI) P value
Overall mortality
Conservative approach 4.83 (2.56–9.00) <.0001 5.84 (2.85–11.9) <.0001
Age 1.11 (1.06–1.15) <.0001 1.07 (1.04–1.11) .0001
LVEDD 0.93 (0.89–0.97) .001
LVESD 0.89 (0.84–0.95) .001
AF 2.02 (1.09–3.76) .03
Hypertension 0.45 (0.22–0.91) .03
Cardiac mortality
Conservative approach 4.31 (1.84–10.10) .001 3.37 (1.22–9.26) .019
Age 1.16 (1.09–1.23) <.0001 1.15 (1.07–1.24) <.0001
Serum creatinine 4.23 (1.81–9.9) .001
LVEDD 0.94 (0.89–0.99) .02
AF 2.89 (1.23–6.51) .01
HR, Hazards ratio; CI, confidence interval; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; AF, atrial fibrillation.A
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Doutweigh the operative risk as well as the long-term valve-
related morbidity and mortality risks. In the past, the oper-
ative mortality of mitral valve replacement was undoubtedly
too high to consider surgery in asymptomatic patients.12
However, with the advent of mitral valve repair, operative
mortality has considerably decreased. As early as in 1996,
Sousa and colleagues23 reported surgical results on a series
of asymptomatic or mildly symptomatic patients who had
mitral valve repair for severe MR. The overall operative
mortality in these patients was 1.7%, 5-year freedom
from reoperation was 97%, and 5-year event-free survival
was 91%. More recently, Ling and colleagues,24 Smolens
and associates,9 and David and coworkers6 reported very
similar results, with operative mortality ranging from 0%The Journal of Thoracic and Cto 0.5% and 5-year overall survival ranging from 90% to
100%.
The good results of valve repair thus make it conceivable
to propose this operation to low-risk, still asymptomatic pa-
tients. The results of the present study fully support this new
paradigm. Degenerative mitral valve disease in our series
was 100% repairable with the initial operative procedure.
There were no patients in our series who had an initial pre-
operative plan of valve repair that ultimately required valve
replacement. In our series, only 2 patients with marked pul-
monary hypertension died in the immediate postoperative
period (30-day mortality of 1.5%). Importantly, there was
no death among patients who were free of any MR compli-
cations at the time of intervention. Long-term survival wasFIGURE 5. Age-adjusted Kaplan-Meier curves for overall (A) and cardiovascular (B) survival compared with patients having early surgery (solid line), those
treated conservatively (dashed line), and the age- and gender-matched Belgian population (dashed dotted line). Numbers at bottom indicate patients at risk.ardiovascular Surgery c Volume 138, Number 6 1345
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ture.6,9,24 Indeed, in our whole series, 5- and 10-year overall
survival was 94% and 86%, respectively. Results were even
better in the subgroup of patients who were free of any MR
complications. In these patients, 5- and 10-year overall sur-
vival was 96% and 89%, respectively. Based on the results
of our study as well as those published in the literature, both
the short- and long-term perioperative risks of mitral valve
repair appear to be minimal, allowing this procedure to be
proposed to low-risk patients with no or minimal symptoms.
Natural History of Severe Degenerative MR
The natural history of medically treated MR is difficult to
delineate, with a wide range of 5-year survival estimates
reported in the literature (from 50% to 90%). In a recent
study, Enriquez-Sarano and colleagues5 studied the out-
comes of 198 asymptomatic patients with severe isolated
MR who were initially treated medically. MR severity was
assessed by the proximal isovelocity surface area method
and defined as severe when the regurgitant volume was
>60 mL and/or the effective regurgitant orifice area was
>40 mm2. In these patients, overall 5-year survival probabil-
ity was only 58%, and most fatalities were of cardiac origin.
The results of the present study confirm those of that earlier
report, with an overall 5- and 10-year survival of 60% and
24%, respectively, in the subgroup of conservatively treated
patients who did not have structured follow-up. Similar re-
sults were also obtained when censoring conservatively fol-
lowed patients at the time of the delayed surgery (data not
shown). Like in the study of Enriquez-Sarano and col-
leagues,5 the survival rate of patients with severe degenera-
tive MR in our study was significantly less than that of the
age- and gender-matched Belgian population, and most fa-
talities were cardiac related.
The results of these previous studies are clearly at vari-
ance with those recently reported by Rosenheck and associ-
ates.7 These authors followed a cohort of 132 consecutive
asymptomatic patients with severe degenerative MR. All
patients prospectively had serial clinical and echocardio-
graphic examinations and were referred for surgery when
the operative criteria described in the guidelines were ful-
filled. During follow-up, 38 patients developed criteria for
surgery and only 8 deaths were observed. Overall survival
including perioperative and late deaths after mitral valve
surgery was 91% at 8 years and was not statistically differ-
TABLE 6. Ten-year propensity-matched score-adjusted hazards ratio
for overall mortality, cardiac mortality, and cardiovascular events for
the conservative treatment
End point 10-year HR 95% CI
Overall mortality 5.21 2.56–10.60
Cardiac mortality 4.83 1.84–12.6
CV events 4.40 2.00–7.90
HR, Hazards ratio; CI, confidence interval; CV, cardiovascular.1346 The Journal of Thoracic and Cardiovascular Sent from expected survival. This suggests that the outcome
of patients with severe MR is better than previously re-
ported, particularly when patients are followed closely in
a structured environment and are referred in a timely man-
ner to surgery according to current guidelines criteria. The
present study, however, questions the good outcome of
asymptomatic patients with severe MR even when they
are being carefully followed and referred in a timely manner
to surgery. To mimic the organized follow-up of Rosenheck
and colleagues,7 we evaluated whether patients who con-
sulted a registered cardiologist at least once a year had
better spontaneous outcomes than patients who did not.
Although our results indicate that the frequency and quality
of follow-up favorably influences the prognosis of patients
treated conservatively, they also show that the overall sur-
vival probability of these patients is still significantly less
than that of patients operated on early after the index diag-
nosis. Even after adjustment for all the baseline characteris-
tics using a propensity score analysis, we found that
patients having early surgery had a significantly better
10-year overall, cardiac, and cardiovascular event–free sur-
vival than those followed conservatively (10-year overall
mortality propensity-matched score-adjusted hazards ratio
for the conservative group was 5.21 [2.56–10.60]). It could
of course be argued that our follow-up was not as strict as
that organized by Rosenheck and coworkers,7 which could
explain why our patient’s outcome was poorer. The fact that
most of our patients were referred to surgery in a timely
manner (within a median of 46 days of newly appearing
guidelines criteria) strongly suggests that this explanation
is unlikely.
Impact of AF and Pulmonary Hypertension
Although AF and pulmonary hypertension are common
complications of chronic severe MR, their implications for
patient management remains uncertain. Indeed, current
American Heart Association/American College of Cardiol-
ogy and European Society of Cardiology guidelines merely
consider AF and pulmonary hypertension as a class IIa indi-
cation, which indicates that there is no clear consensus
among experts to propose surgery in these patients.3,4 Al-
though most previous studies have demonstrated that the
presence of AF and pulmonary hypertension negatively af-
fects outcome in patients with severe MR,25,26 the impact
of surgery in these particular patients remains largely un-
known. To the best of our knowledge, the present study is
the first to address this issue. Our results confirm that the
presence of AF, pulmonary hypertension, or both has a neg-
ative impact on the survival probability in patients initially
treated conservatively. Our results also show that neither
of these complications significantly reduces life expectancy
in patients who are operated on early after the index diagno-
sis. Despite the small number of asymptomatic patients pre-
senting with these complications in our study, we feel that onurgery c December 2009
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ence of AF and/or pulmonary hypertension should probably
be classified as class I instead of the current class IIa.
Survival in Patients Free From Any MR
Complications
The present study is the first to report outcome data in
asymptomatic patients with severe MR but without LV dila-
tation or dysfunction, AF, or pulmonary hypertension. All
previous studies indeed included a small but definite number
of patients presenting with LV dilatation, LV dysfunction,
AF, pulmonary hypertension, or a combination thereof.5-7,9
The large number of patients without any of these complica-
tions in our study clearly reflects our bias toward early sur-
gical intervention in this patient population. This strategy is
supported by the excellent short- and long-term results ob-
tained with early surgery in this group of patients. In our se-
ries, there were no perioperative deaths and only 4 patients
experienced a perioperative morbid event, for a cumulative
operative morbidity risk of 5%. As indicated above, the 5-
and 10-year overall survival of these patients was 96%
and 89%, respectively. By comparison, the 5- and 10-year
overall survival of similar patients being followed more con-
servatively was significantly less (ie, 78% and 62%, respec-
tively). As in other subgroups of asymptomatic patients,
these data reinforce the hypothesis that most patients with
severe MR should be offered an early surgical option when-
ever their valve is repairable and a skillful surgeon is avail-
able for performing the repair.
Limitations to the Study
There are several limitations to this study that should be
acknowledged. First, despite the completeness of our fol-
low-up data and the prospective nature of the database
from which the data were retrieved, our study has a retro-
spective design and the patients were not randomized
between the early surgical strategy and the more conserva-
tive approach. Although the different groups were relatively
well balanced at baseline, we cannot exclude the possibility
that unaccounted confounding factors contributed to our re-
sults. There is no doubt that a prospective randomized trial
would provide a definite demonstration of the superiority
of mitral reconstruction in patients with no symptoms or
mild symptoms. Unfortunately, it is quite unlikely that
such a trial can ever be conducted in today’s time, as it would
be judged unethical by many surgeons and cardiologists.
Second, patients were deemed asymptomatic or mildly
symptomatic on the basis of the New York Heart Associa-
tion functional classification, which has obvious intrinsic
limitations. Ideally, patients should have been classified ac-
cording to the results of an exercise test. Unfortunately, be-
cause of the retrospective design of our study, these data
were unavailable in a large majority of our patients. Finally,
no quantitative measurements of the regurgitant orifice area,The Journal of Thoracic and Cthe regurgitant volume, or the vena contracta were used in
the present study, mainly because these measures were not
part of a standard echocardiographic examination at the
time the patients were recruited. Yet, the careful, integrated
approach to semiquantitative assessment of MR is in full
agreement with the prevailing guidelines.27 Finally, it would
have been interesting to obtain follow-up echocardiographic
data in the 2 groups of patients to get more insights into the
mechanisms underlying the observed differences in out-
come. Unfortunately, the retrospective design of this work
did not allow collecting these data.
Our data demonstrate that overall, cardiovascular, and
event-free survival of patients with severe degenerative
MR is better when opting for an early surgical rather than
for a more conservative treatment strategy. Our data also
demonstrate that the survival benefits seen in patients having
early surgery are present in all patient’s subgroups, including
patients without any MR complications (ie, without LV dila-
tation, LV dysfunction, AF, or pulmonary hypertension).
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